1331775-09-7

Upstream product

• 6547-53-1 2-[4-(benzyloxy)benzyl]acetic acid 
• 109-72-8 n-butyllithium 
• 243641-09-0 2-[4-(Benzyloxy)phenyl]-N-methoxy-N-methylacetamide 
• 693-04-9 butyl magnesium bromide 

Downstream Products

• 1415596-10-9 C₂₅H₂₂ClNO₂S 
• 1415596-26-7 C₃₂H₃₇ClN₂O₂S 
• 1415596-24-5 C₃₃H₃₇ClN₂O₂S 
• 1415596-08-5 C₃₂H₂₈ClNO₂S 
• 1331775-18-8 4-(4-benzyloxyphenyl)-3-butyl-6-(1-methylpiperidin-4-ylmethoxy) pyridazine hydrochloride 
• 1331775-60-0 4-[3-butyl-6-(1-methyl-piperidin-4-yloxy)pyridazin-4-yl]phenol 
• 1331775-21-3 4-(4-benzyloxyphenyl)-3-butyl-6-(3-piperidin-1-ylpropoxy) pyridazine 
• 1331775-20-2 {3-[5-(4-benzyloxyphenyl)-6-butylpyridazin-3-yloxy]-propyl} diethylamine 
• 1331775-19-9 {2-[5-(4-benzyloxyphenyl)-6-butylpyridazin-3-yloxy]-ethyl} diethylamine 
• 1331773-95-5 4-(4-benzyloxyphenyl)-3-butyl-6-(1-methylpiperidin-4-ylmethoxy)pyridazine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease

A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on Aβ-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on Aβ-RAGE binding. Compounds selected from Aβ-RAGE binding screening displayed inhibitory activity on Aβ transport across BBB. They also showed inhibitory activity against Aβ-induced NF-κB activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD.

PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF

The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.